EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Abstract 15840: Efficacy and Safety of Baxdrostat in Resistant Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Vamsi Pachchipulusu, Nikhitha Konda, Nagaraj Sanchitha Honganur, Revanth Reddy Bandaru, Sorabh Sharma, Harshawardhan Dhanraj Ramteke, Rakhshanda khan, Anthony Al-Dehneh

Circulation · 02.11.2026 · 154 (Suppl_1)

DOI: 10.1161/circ.154.suppl_1.15840 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Vamsi Pachchipulusu und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Resistant hypertension remains a major unmet clinical challenge despite optimized multidrug therapy. Aldosterone dysregulation plays a central role in its pathophysiology. Baxdrostat, a selective aldosterone synthase inhibitor, has emerged as a novel therapeutic strategy. This meta-analysis evaluated its pooled efficacy and safety across randomized controlled trials.

Methods

We conducted a systematic review and random-effects meta-analysis of six randomized controlled trials to evaluate the dose-specific efficacy and safety of baxdrostat in resistant hypertension.

Results

A total of six randomized controlled trials comprising 1,319 patients were included in the pooled analysis. Of these, 923 patients received baxdrostat (2 mg, n=399; 1 mg, n=394; 0.5 mg, n=130), and 396 received placebo. The pooled population represented a high-risk resistant hypertension cohort, with a weighted mean age of 61.2 years, mean BMI of 31.7 kg/m 2 , 58.9% male participants, 38.5% with diabetes, and a baseline systolic blood pressure (SBP) of 148.6 mmHg. In the primary efficacy analysis, baxdrostat 2 mg demonstrated a statistically significant placebo-corrected reduction in SBP at 12 weeks (–7.99 mmHg; 95% CI, –12.57 to –3.41; P < 0.001), with moderate to substantial heterogeneity (I 2 = 72.8%). The 1 mg and 0.5 mg doses showed smaller, non-significant reductions in SBP. Regarding safety, baxdrostat was associated with a significantly increased risk of severe hyperkalemia (K > 6.0 mmol/L) compared with placebo (RR 5.46; 95% CI, 1.22-14.47; I 2 = 0.0%), although absolute event rates were low.

Conclusions

In patients with resistant hypertension, baxdrostat 2 mg was associated with reduced systolic blood pressure compared with placebo. These findings support selective aldosterone synthase inhibition as a promising therapeutic strategy for resistant hypertension, although careful potassium monitoring remains necessary.

Zitieren

APA

Pachchipulusu, V., Konda, N., Honganur, N. S., Bandaru, R. R., Sharma, S., Ramteke, H. D., khan, R., & Al-Dehneh, A. (2026). Abstract 15840: Efficacy and Safety of Baxdrostat in Resistant Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.15840

Vancouver

Pachchipulusu V, Konda N, Honganur NS, Bandaru RR, Sharma S, Ramteke HD, et al. Abstract 15840: Efficacy and Safety of Baxdrostat in Resistant Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.15840

BibTeX
@article{Pachchipulusu2026,
  author = {Pachchipulusu, Vamsi and Konda, Nikhitha and Honganur, Nagaraj Sanchitha and Bandaru, Revanth Reddy and Sharma, Sorabh and Ramteke, Harshawardhan Dhanraj and khan, Rakhshanda and Al-Dehneh, Anthony},
  title = {Abstract 15840: Efficacy and Safety of Baxdrostat in Resistant Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {Suppl_1},
  doi = {10.1161/circ.154.suppl_1.15840}
}
Kostenlos starten →